Trial Profile

A Phase III clinical trial of Siltartoxatug for Tetanus .

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siltartoxatug (Primary)
Indications Tetanus
Focus Adverse reactions; Registrational

Most Recent Events

08 Jan 2026 New trial record
12 Dec 2025 According to Zhuhai Trinomab Pharmaceutical media release, engaged in discussions with the FDA regarding the regulatory pathway for Siltartoxatug Injection in the United States and plans to further align with the agency on the design and protocol of a U.S.-based Phase III clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com